Atossa Genetics (NasdaqCM: ATOS) Annual Shareholder Meeting April 12 – Vote Proxy By Calling 1-877-777-8133
Seattle based Atossa Genetics (NasdaqCM: ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, is holding its Annual Shareholder Meeting tomorrow, April 12th in New York City (complete details are in the letter below).
Shareholders are reminded to cast their votes by calling 1-877-777-8133. You can review the complete SEC filing of Atossa’s Proxy here.
In Atossa’s SEC filing the Proxy leads off with the following note from CEO Steven Quay:
You are cordially invited to attend the Annual Meeting of Stockholders of Atossa Genetics Inc., a Delaware corporation (the “Company”), which will be held on April 12, 2018, at 1:00 p.m. Eastern time, at the offices of Pryor Cashman LLP, 7 Times Square (42nd and Broadway, SW corner), 40th Floor, Room A, New York, New York 10036-6569. Only stockholders of record who held common stock at the close of business on the record date, March 12, 2018 (the “Record Date”), may attend and vote at the Annual Meeting, including any adjournment or postponement thereof.
At the Annual Meeting, you will be asked to consider and vote upon: (1) the election of two Class III directors named in the Proxy Statement; (2) the ratification of the selection of BDO USA LLP (“BDO”) as our independent registered public accounting firm for the fiscal year ending December 31, 2018; (3) the approval to increase authorized shares under the Atossa Genetics 2010 Stock Option and Incentive Plan (the “Plan”) by 6,000,000 shares; (4) approval of an amendment (in the event it is deemed by the Board of Directors to be advisable) to the certificate of incorporation to effect a reverse stock split of the issued and outstanding shares of common stock at a ratio within the range of 3:1 up to a split of 15:1, as determined by the Board of Directors; (5) approval of an amendment to the certificate of incorporation to increase the number of shares of authorized common stock by 100 million; (6) an advisory (non-binding) vote on the Company’s executive compensation; (7) an advisory (non-binding) vote on the frequency of future advisory votes on executive compensation; and (8) the transaction of any other business that may properly come before the meeting or any adjournment thereof.
No other items of business are expected to be considered at the meeting and no other director nominees will be entertained, pursuant to the Company’s Bylaws. The enclosed Proxy Statement more fully describes the details of the business to be conducted at the Annual Meeting. After careful consideration, our Board of Directors has unanimously approved the proposals and recommends that you vote FOR each nominee and FOR each other proposal. After reading the Proxy Statement, please mark, date, and sign and return the enclosed proxy card in the accompanying reply envelope to ensure receipt by our tabulator. YOUR SHARES CANNOT BE VOTED UNLESS YOU SIGN, DATE AND RETURN THE ENCLOSED PROXY OR ATTEND THE ANNUAL MEETING IN PERSON. Stockholders of record on the record date may also vote on-line or by phone by following the instructions contained in the accompanying Proxy Statement.
A copy of the Atossa Genetics Inc. 2017 Annual Report has been mailed with this Proxy Statement to all stockholders entitled to notice of and to vote at the Annual Meeting.
We look forward to seeing you at the Annual Meeting.
Steven C. Quay, M.D., Ph.D.
Chairman of the Board, President and
Chief Executive Officer
March 18, 2018
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive!